[go: up one dir, main page]

ZA200900905B - Modified-galactosyl ceramides for staining and stimulating Natural Killer T cells - Google Patents

Modified-galactosyl ceramides for staining and stimulating Natural Killer T cells

Info

Publication number
ZA200900905B
ZA200900905B ZA200900905A ZA200900905A ZA200900905B ZA 200900905 B ZA200900905 B ZA 200900905B ZA 200900905 A ZA200900905 A ZA 200900905A ZA 200900905 A ZA200900905 A ZA 200900905A ZA 200900905 B ZA200900905 B ZA 200900905B
Authority
ZA
South Africa
Prior art keywords
staining
cells
modified
natural killer
stimulating natural
Prior art date
Application number
ZA200900905A
Other languages
English (en)
Inventor
Paul B Savage
Luc Teyton
Albert Bendelac
Original Assignee
Scripps Research Inst
Univ Brigham Young
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Brigham Young, Univ Chicago filed Critical Scripps Research Inst
Publication of ZA200900905B publication Critical patent/ZA200900905B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200900905A 2006-04-07 2009-02-06 Modified-galactosyl ceramides for staining and stimulating Natural Killer T cells ZA200900905B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79009606P 2006-04-07 2006-04-07

Publications (1)

Publication Number Publication Date
ZA200900905B true ZA200900905B (en) 2010-06-30

Family

ID=38581864

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900905A ZA200900905B (en) 2006-04-07 2009-02-06 Modified-galactosyl ceramides for staining and stimulating Natural Killer T cells

Country Status (12)

Country Link
US (2) US8227581B2 (fr)
EP (1) EP2056842B1 (fr)
AU (1) AU2007234753B2 (fr)
BR (1) BRPI0710668A2 (fr)
CA (1) CA2661789C (fr)
DK (1) DK2056842T3 (fr)
ES (1) ES2397975T3 (fr)
PL (1) PL2056842T3 (fr)
PT (1) PT2056842E (fr)
SI (1) SI2056842T1 (fr)
WO (1) WO2007118234A2 (fr)
ZA (1) ZA200900905B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
JP5053101B2 (ja) 2005-01-28 2012-10-17 ブリガム ヤング ユニヴァーシティー ＣＤ１ｄ−拘束ＮＫＴ細胞の細菌糖脂質による活性化
US7794722B2 (en) 2006-06-30 2010-09-14 The Scripps Research Institute Adjuvants and methods of use
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
AU2013202869B2 (en) * 2007-11-07 2015-10-22 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2058011A1 (fr) * 2007-11-07 2009-05-13 Wittycell Cellule Nkt activant des antigènes et/ou médicaments à liaison gycolipids covalentyl
BRPI0820960B8 (pt) 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
CA2739765A1 (fr) * 2008-10-08 2010-04-15 Vincent Serra Composition vaccinale utilisable contre la grippe
ES2345377B1 (es) * 2009-03-20 2011-07-21 Consejo Superior De Investigaciones Cientificas (Csis) (51%) Compuestos aminociclitoles, procedimiento de obtencion y usos.
CA2792754C (fr) 2010-03-12 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ?-mannosylceramide et stimulation de l'immunite anticancereuse de cellules nkt
KR102099764B1 (ko) 2012-04-26 2020-04-10 리가가쿠 겐큐쇼 신규 카르바메이트 당지질 및 그 용도
EP3296309B1 (fr) * 2012-06-28 2019-08-07 Universiteit Gent Dérivés de galactopyranosyle utiles en tant que médicaments
EP2727929A1 (fr) * 2012-10-30 2014-05-07 Wittycell Procédé de préparation de composés de céramides avec un radical alpha galactosyle
WO2014210522A1 (fr) * 2013-06-28 2014-12-31 The Scripps Research Institute Ligands de cellules nkt et procédés d'utilisation
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
CN110831629B (zh) * 2016-09-14 2022-08-23 Abivax公司 用于治疗癌症的包括abx196的组合
EP3774830A1 (fr) * 2018-03-26 2021-02-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Analogues de 3-o-sulfo-galactosylcéramide en tant qu'activateurs de cellules nkt de type ii et leurs procédés d'utilisation
US20250049904A1 (en) * 2021-12-24 2025-02-13 Victoria Link Limited Immunostimulatory compositions
CN115286667B (zh) * 2022-08-02 2024-03-26 华中农业大学 一种α-半乳糖基神经酰胺类似物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (fr) * 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (fr) * 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Nouveau sphingoglycolipide et son utilisation
CA2160566C (fr) * 1993-04-15 2004-07-13 Tatsuo Higa Nouveaux sphingoglycolipides et leurs utilisations
HUT74506A (en) * 1993-05-14 1997-01-28 Cytel Corp Sialyl lewis-x analogues as inhibitors of cellular adhesion
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (fr) * 1996-03-29 1999-06-02 Rohm And Haas Company Sphinogolipides et procédé pour ceux-ci
WO1998034623A1 (fr) 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Composition lyophylisee a base de glycosphingolipide et procede de fabrication
US6417167B1 (en) * 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
US6492337B1 (en) 1997-12-30 2002-12-10 A+ Science Ab Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complication
CA2320117A1 (fr) * 1998-02-12 1999-08-19 Emory University Derives de sphingolipides et procedes d'utilisation
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2001082935A1 (fr) * 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedes contre le cancer
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
US20020115624A1 (en) * 2000-06-22 2002-08-22 Behar Samuel M. Alpha gylcosylceramides for treating bacterial and fungal infections
WO2002018539A2 (fr) * 2000-08-25 2002-03-07 Lysometrix Corporation Procede permettant d'analyser l'activite des enzymes lysosomales
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
KR20050043736A (ko) * 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
EP1551228B1 (fr) * 2002-06-13 2012-10-03 New York University C-glycolipide de synthese et utilisation de celui-ci pour le traitement du cancer, des maladies infectieuses et des maladies auto-immunes
EP1611147A4 (fr) * 2003-03-20 2007-10-17 Univ Brigham Young 6"-amino-6"-deoxygalactosylceramides
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
AU2005235080A1 (en) * 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
CA2577009C (fr) 2004-08-27 2017-05-02 Steven A. Porcelli Derives de ceramides utilises comme modulateur d'immunite et d'auto-immunite
US7998739B2 (en) * 2004-09-03 2011-08-16 The Scipps Research Institute Methods of activating NKT cells
AU2005322027B2 (en) * 2004-12-28 2013-09-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NK Tcells
JP5053101B2 (ja) * 2005-01-28 2012-10-17 ブリガム ヤング ユニヴァーシティー ＣＤ１ｄ−拘束ＮＫＴ細胞の細菌糖脂質による活性化
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
CA2626997C (fr) 2005-10-25 2014-12-23 Ludwig Institute For Cancer Research Analogues de l'alpha-galactosylceramide et applications
US7794722B2 (en) * 2006-06-30 2010-09-14 The Scripps Research Institute Adjuvants and methods of use
EP1938836A1 (fr) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprenant une sous-unité B de la toxine dysentérique et moyen de stimulation des cellules NKT

Also Published As

Publication number Publication date
SI2056842T1 (sl) 2013-02-28
US20090047299A1 (en) 2009-02-19
DK2056842T3 (da) 2013-01-14
EP2056842B1 (fr) 2012-10-17
EP2056842A4 (fr) 2010-10-06
AU2007234753A1 (en) 2007-10-18
WO2007118234A3 (fr) 2007-12-06
EP2056842A2 (fr) 2009-05-13
ES2397975T3 (es) 2013-03-12
AU2007234753B2 (en) 2013-02-21
BRPI0710668A2 (pt) 2011-08-16
US8765692B2 (en) 2014-07-01
CA2661789A1 (fr) 2007-10-18
US20120270815A1 (en) 2012-10-25
WO2007118234A2 (fr) 2007-10-18
US8227581B2 (en) 2012-07-24
CA2661789C (fr) 2014-06-03
PT2056842E (pt) 2013-01-24
PL2056842T3 (pl) 2013-03-29

Similar Documents

Publication Publication Date Title
ZA200900905B (en) Modified-galactosyl ceramides for staining and stimulating Natural Killer T cells
IL202329A0 (en) Methods and compositions for stimulating cells
PT2066399T (pt) Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos
EP2089507A4 (fr) Dispositifs et procédés particulièrement efficaces dans la culture de cellules
AP3322A (en) Cell assay kit and method
IL221384A0 (en) Improving il-15 and il-15r-alpha for expression in mammalian cells
GB2479680B (en) Refuge chamber and method
ZA200810290B (en) Grain refiners for steel-manufacturing methods and use
EP2095098A4 (fr) Procédés et structure de support d'échantillon
SG10201510384UA (en) Cell culture improvements
IL197781A0 (en) Lyophilization methods and apparatuses
IL204682A0 (en) Artificial marble and methods
ZA200804851B (en) Compositions and methods for cell killing
PL2102354T3 (pl) Urządzenie i sposoby osmotycznego szokowania komórek
IL247957A0 (en) Anti-ephrinb2 antibodies and methods of using them
EP2227540A4 (fr) Dédifférenciation de cellules humaines
GB0605702D0 (en) Materials and methods for immune cell stimulation
GB0700302D0 (en) Method and kit
IL201346A0 (en) Newcompositions and methods for cell killing
EP1871914A4 (fr) Procédés et compositions destinés à l'introduction de biopolymères dans des cellules
EP2115127A4 (fr) Procédés et compositions pour améliorer la santé de cellules en culture
GB0606671D0 (en) Cell Culture
GB0701037D0 (en) Grooming aid and related methods
EP2185685A4 (fr) Nouveaux procédés et nouvelles lignées cellulaires
GB0715201D0 (en) Flavonoids-rich tissues from neomarica gracilis and methods for culturing the same